Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.07 · 8-K

Cel-Sci Corporation

CVMNYSE_AMERICANEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Securities Holders. The annual meeting of CEL-SCI’s shareholders was held on August 14, 2026. At the meeting the following persons were elected as directors for the upcoming year:…

Filed Aug 17, 2026Accepted Aug 17, 2026, 9:05 AM EDTCIK 725363Accession 0001654954-26-007691
Share

Company context

We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:

Current securities

Historical securities (1)

Recent company filings

  1. S-8 filingSep 3, 2026
  2. 10-Q filingAug 14, 2026
  3. ARS filingJul 2, 2026
  4. DEF 14A filingJul 2, 2026
  5. Entry into a Material Definitive Agreement · Other EventsJun 16, 2026

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Securities Holders. The annual meeting of CEL-SCI’s shareholders was held on August 14, 2026. At the meeting the following persons were elected as directors for the upcoming year: Name Votes For Votes Withheld Broker Non-Votes ────────────────────────────────────────────────────────────────────────────── Geert Kersten 4,371,909 478,675 4,365,596 Bruno Baillavoine 2,188,254 2,662,330 4,365,596 Robert Watson 2,062,150 2,788,434 4,365,596 At the meeting the following were approved by CEL-SCI’s shareholders: (2) the adoption of CEL-SCI’s 2026 Non-Qualified Stock Option Plan; and (3) the adoption of CEL-SCI’s 2026 Stock Bonus Plan; (4) to approve, on a non-binding advisory basis, the compensation of CEL-SCI’s executive officers; (5) to approve, on a non-binding advisory basis, the frequency of the advisory vote regarding the compensation of CEL-SCI’s executive officers; and (6) to ratify the appointment of BDO USA, LLP as CEL-SCI’s independent registered public accounting firm for the fiscal year ending September 30, 2026; and The following is a tabulation of votes cast with respect to proposals 2, 3, 4 and 6: Proposal Votes For Votes Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────────────────────────── (2) 3,654,395 1,144,219 51,970 4,365,596 (3) 3,793,843 997,808 58,933 4,365,596 (4) 3,777,031 1,010,124 63,429 4,365,596 (6) 8,638,163 364,150 213,867 0 The following is a tabulation of votes cast with respect to proposals 5: Proposal 1 Year 2 Years 3 Years Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────────── (5) 1,692,789 158,296 2,668,661 330,838 4,365,596